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AJOG at a Glance 
 
Why was the study conducted? 
Vaginal cerclage is recommended in women with recurrent mid-trimester loss or early 
preterm birth. When vaginal cerclage fails, transabdominal cerclage has been advocated, 
with observational studies suggesting higher rates of success. We searched PubMed for 
original articles published in English prior to September 2018 with the search terms 
“spontaneous preterm birth OR cerclage OR transabdominal cerclage OR high vaginal 
cerclage”. There were no randomised studies that compared abdominal versus repeat 
vaginal cerclage.  
 
What are the key findings?  
This randomised controlled trial provides the first direct comparison of abdominal and 
high vaginal cerclage with low vaginal cerclage. Abdominal cerclage was demonstrated to 
be superior to low vaginal cerclage in women with prior failed cerclage in preventing 
early preterm birth (less than 32 weeks) and fetal loss. High vaginal cerclage was no better 
than low vaginal cerclage in preventing early birth.  
 
What does this study add to what is already known?  
Women with a prior failed vaginal cerclage (pregnancy delivered before 28 weeks of 
gestation) should be offered an abdominal cerclage, either before or in early pregnancy.  
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ABSTRACT  
Background 
Vaginal cerclage (a suture around the cervix) is commonly placed in women with recurrent pregnancy loss. 
These women may experience late miscarriage or extreme preterm delivery, despite being managed with 
cerclage.  
Objective 
Transabdominal cerclage (TAC) has been advocated following failed cerclage, although its efficacy is unproven 
by randomised controlled trial (RCT).  
Study Design 
A multicentre RCT to compare TAC or high vaginal cerclage (HVC) to low vaginal cerclage (LVC), as a 
preventative strategy for spontaneous preterm birth (sPTB) in women with history of a failed cerclage was 
undertaken. Women were randomly assigned (1:1:1) to receive TAC, HVC or LVC, either prior to conception or 
before 14 weeks’ gestation.  Primary outcome was delivery before 32 completed weeks of pregnancy.  
Results 
111/139 women recruited who conceived were analysed: 39 to TAC, 39 to HVC and 33 to LVC. Rates of 
sPTB<32 weeks were significantly lower in women who received a TAC compared to LVC [8% (3/39) v 38% 
(15/39), RR 0.23 (95% CI 0.07 to 0.76), p=0.0078]. Number needed to treat (NNT) to prevent one sPTB was 3.9 
(95% CI 2.2 to 13.3). There was no difference in sPTB rates between HVC and LVC [38% (15/39) vs 33% 
(11/33), RR 1.15 (95% CI 0.62 to 2.16), p=0.81]. No neonatal deaths occurred. Women with TAC had fewer 
fetal losses compared to LVC [3% (1/39) vs 21% (7/33), RR 0.12 (95% CI 0.016 to 0.93), p=0.02]. NNT to 
prevent one fetal loss was 5.3 (95% CI 2.9 to 26).  
Conclusions 
TAC is the treatment of choice for women with failed vaginal cerclage. It is superior to LVC in reducing risk of 
early PTB and fetal loss in women with previous failed vaginal cerclage. HVC does not confer this benefit. 
NNT are sufficiently low to justify transabdominal surgery and caesarean delivery required in this select cohort.    
 5 
BACKGROUND  
Recurrent late miscarriage and early preterm birth is often treated with vaginal cerclage (a suture placed around 
the cervix). This is known to have a significant benefit in a small number of cases probably representing those 
with genuine cervical incompetence, or who have traumatic cervical damage, such as that caused by surgery(1). 
When evaluated by randomised controlled trial (RCT), vaginal cerclage (VC) has limited value, compared to 
conservative management (1:25)(2). Even without cerclage, most women will have a successful subsequent 
pregnancy. The challenge is to identify those women whose pregnancy losses are genuinely due to cervical 
weakness; women who experience multiple late miscarriages or early preterm births are more likely to fall into 
that category.  
In women for whom vaginal cerclage fails, abdominal cerclage (TAC, inserted laparoscopically or via 
laparotomy) has been advocated but requires more extensive surgery than vaginal cerclage, and caesarean 
delivery. A number of observational series(3–6) have suggested that abdominal cerclage is highly successful, 
however abdominal cerclage has never been evaluated in an RCT.  
 
We hypothesised that abdominal cerclage (TAC) would result in lower rates of late miscarriage and early 
preterm delivery compared to low vaginal cerclage (LVC) by maintaining structural and biochemical integrity 
of the cervix because it is placed higher in the cervix, ideally at the level of the internal os. This may prevent the 
infective/inflammatory cascade associated with cervical shortening(7), which may be due either to stretch of the 
fetal membranes as the internal os opens(8), or loss of the cervical barrier to ascending infection(7). A VC can 
also be placed higher in the cervix, by mobilising the bladder (HVC). It is unknown whether this also results in 
lower rates of late miscarriage or PTB when compared to LVC.  
 
METHODS 
Study design and participants 
The MAVRIC trial was a multicentre RCT funded by the J P Moulton Charitable Foundation, and supported by 
the NIHR Clinical Research Network (CRN). NHS Research Ethical Committee approval was obtained (REC 
07/H1102/113) and the trial was registered on the International Standard Randomised Controlled Trial Registry 
(ISRCTN33404560).  
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Women were eligible for trial inclusion if they had a history of spontaneous late miscarriage or preterm birth 
before 28 completed weeks of pregnancy with low vaginal cerclage (LVC) in situ, but excluding rescue cerclage 
procedures, i.e. cerclage inserted with exposed membranes. Women were eligible for randomisation pre-
conceptually or at less than 14 weeks’ gestation.  
Participants were referred from hospitals across the United Kingdom and recruited at 9 sites (London (4 sites), 
Kirkcaldy, Sunderland, Newcastle, Bradford and Edinburgh) between January 2008 and September 2014. All 
participants gave written informed consent, and were over the age of 16. 
 
Procedures 
Women with a previous failed cerclage were randomised to one of the following: 
1. TAC: Transabdominal cerclage 
2. HVC: High vaginal cerclage  
3. LVC: Low vaginal cerclage  
Techniques used were left to the local clinician’s discretion. Details of surgical and anaesthetic technique were 
collected. Vaginal cerclage was inserted prior to 16 weeks’ under regional anaesthetic and removed at 37 weeks' 
gestation, or earlier if preterm labour ensued. HVC involved mobilisation of the bladder from the anterior cervix 
allowing the suture to be placed higher, and usually required regional anaesthetic for removal.  TAC was placed 
pre-conceptually or before 14 weeks' gestation as an open procedure under either regional or general 
anaesthetic, requiring inpatient stay of up to 3 days. Women with TAC were delivered by elective caesarean 
section at 38 to 39 weeks, with retention of the TAC for future pregnancies. All first trimester miscarriages (less 
than 13 weeks’) post randomisation were excluded from the analysis (3 excluded: 1 in TAC, 1 in HVC and 1 in 
LVC group).   
 
Randomisation and masking 
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Women enrolled in MAVRIC were randomly assigned to TAC, HVC or LVC (1:1:1) using a computer-
generated randomisation procedure incorporated in an internet-based secure trial database 
(www.medscinet.net/MAVRIC). Minimisation was used to balance two prognostic variables: pregnancy at time 
of randomisation and gestational age of previous late miscarriage or preterm delivery (Table 1).  Due to the 
nature of the interventions, treatment allocation was known to both participants and health care professionals. 
Written informed consent was obtained from all participants and baseline demographic characteristics, risk 
factors and obstetric and gynaecologic history were entered into the study specific database.  
Cerclage insertion was performed electively between 10 to 16 weeks’ (14 weeks for TAC) or pre-conception if 
assigned to TAC or HVC, according to clinician and patient preference. All LVCs were carried out at the 
women’s local maternity unit. As HVCs and TACs are more specialist procedures, these were carried out in one 
of the designated centres, to ensure a suitably experienced surgeon completed the procedure. Following cerclage 
insertion, women were monitored and managed according to local clinicians’ practice. All care was in line with 
contemporaneous evidence-based guidelines.  
 
Outcomes 
Our primary outcome on which the trial was powered, was delivery before 32 completed weeks of pregnancy. 
Pre-defined secondary outcomes included neonatal death, serious operative complication rates and 
complications of pre- and post-conception cerclage (HVC and TAC).  
Pregnancy outcomes were obtained from case note review, by trained research midwives. Women were 
considered to have had a spontaneous preterm birth (sPTB) if they had spontaneous onset of labour, or 
experienced preterm rupture of membranes and delivered prematurely, regardless of mode of delivery. There 
were no changes to pre-specified outcomes during recruitment. All pre-specified analyses were undertaken. As 
there were no neonatal deaths, we compared the overall fetal loss rate by trial arm (composite of late miscarriage 
and stillbirth).  
 
Sample size calculation 
Sample size estimation was informed by data from an observational study by Davis et al. (4), the best available 
evidence at the time. Our primary outcome was rate of delivery before 32 complete weeks of gestation. 
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Assuming a baseline event rate of 38% with LVC and 10% with TAC (4), a total of 43 women in each of the 
three groups (TAC, HVC and LVC) was required for 80% power, at the 5% significance level (2-tailed), to 
show a significant difference between LVC and the other two groups.   
  
Statistical analysis 
Statistical analyses were undertaken in Stata version 14·2 (StataCorp 15.1, College Station, Texas). Analysis 
was by intention to treat (pre-specified in the protocol), with planned comparison of treatment effects for binary 
endpoints using risk ratios and significance tests for both primary and secondary endpoints. We also performed 
a per protocol analysis, although this was not predefined. 
 
Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing 
of the report. 
 
RESULTS 
Participants 
This was a multicentre RCT, with patients as the unit of randomisation. The full study protocol can be found on 
the King’s College London website 
(https://www.kcl.ac.uk/lsm/research/divisions/wh/clinical/open/mavric.aspx). 
139 participants were recruited and randomly allocated a treatment. The first patient was recruited in January 
2008. Recruitment ended in January 2014, when the planned recruitment target (n=129) had been exceeded. 
Seventy nine women were not pregnant at the time of randomisation, which was a higher number than 
anticipated. At this time 104 women had conceived. Four years later, only 7 additional women had conceived 
and delivered (1 in 2014, 4 in 2015 and 2 in 2017). Despite extensive efforts, we were unable to trace the 
outcomes of two participants who were known to have moved abroad.  The data monitoring committee was 
consulted in September 2018; there had been no further conceptions during the preceding 12 months, and 
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therefore the decision was made to proceed with analysis. Analysis was performed on the 111 women with 
outcome data in September 2018 (see Figure 1). 
 Of the 111 participants who had conceived and with known outcome, 39 were randomised to TAC, 39 to HVC 
and 33 to LVC. Baseline demographic characteristics are shown in Table 2. Patients were managed as per local 
clinical practices: 17% (6/36) of women allocated to TAC were also prescribed progesterone, 28% (10/36) with 
HVC and 48% (14/29) with LVC. All women had a history of recurrent early delivery: the median number of 
late miscarriages was 2 (IQR 1 to 5) and preterm births were 1 (IQR 0 to 5).  
 
Outcomes 
There was a statistically significant reduction in preterm birth less than 32 completed weeks’ gestational age 
(the primary outcome) in women allocated to TAC compared to LVC  [8% (3/39) v 38% (15/39), RR 0⋅ 23 
(95% CI 0⋅ 07 to 0⋅ 76) p=0⋅ 0078]. There were no iatrogenic preterm deliveries among these women. Number 
needed to treat (NNT) to prevent one sPTB was 3⋅ 9 (95% CI 2⋅ 2 to 13⋅ 3). There was no difference in rates 
of sPTB between high and low VC [38% (15/39) vs 33% (11/33), RR 1⋅ 15 (95% CI 0⋅ 62 to 2⋅ 16), p=0⋅ 81]. 
TAC also demonstrated benefit when compared to HVC [8% (3/39) v 38% (15/39), RR 0⋅ 2 (95% CI 0⋅ 063 to 
0⋅ 64), p=0⋅ 0024]. NNT was 3⋅ 2 (95% CI 2⋅ 0 to 7⋅ 4) (see Figure 2).  
No neonatal deaths occurred. Women with a TAC had fewer fetal losses (late miscarriage or stillbirth), 
compared to LVC [3% (1/39) vs 21% (7/33), RR 0⋅ 12 (95% CI 0⋅ 016 to 0⋅ 93), p=0⋅ 02]. NNT to prevent 
one fetal loss was 5⋅ 3 (95% CI 2⋅ 9 to 26).  
 
Serious adverse events (pre-defined as per protocol) were reported in four cases (2 x cervical tears, 1 x ITU 
admission with sepsis and 1 case of cardiomyopathy), all of which occurred in women with high (n=3) or low 
(n=1) vaginal cerclage. 6 women received a subsequent rescue cerclage (2 who were allocated HVC, 2 who 
were allocated LVC). Table 6 gives surgical and anaesthetic details for each procedure divided by outcome; no 
specific trends are apparent and techniques are equally spread across the outcome groups.  
72% (28/39) of women with a TAC in situ delivered at term, compared to fewer than half of women with HVC 
(46%, 18/39) or LVC (48%, 16/33) (Table 4).  
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Eight women did not receive treatment as per allocation (see Table 5), as a result of patient choice following 
randomisation or treatment allocation being judged inappropriate, for example, the cervix was found to be too 
short on vaginal examination at time of procedure. Results are presented by intention to treat however, as shown 
in Table 7, were similar when analysed as per protocol.  
 
DISCUSSION 
Principle Findings 
This is the first RCT comparing abdominal cerclage with vaginal cerclage.  Our findings show that 
transabdominal cerclage is superior to low vaginal cerclage in preventing early PTB and fetal loss (late 
miscarriage and stillbirth) for women with an unsuccessful previous vaginal cerclage pregnancy. Compared to 
LVC, there was no benefit of HVC.  
 
Clinical Implications 
Numbers needed to treat were modest to both prevent delivery before 32 weeks (<4) and to prevent fetal loss 
(<6), and therefore the uptake of this procedure is likely to be efficient and cost effective. Further work should 
establish the health economic impact of such procedures including the longer-term need for caesarean sections 
and associated morbidity. 
 
Strengths and limitations 
Although our numbers were small, they were based on an anticipated large treatment effect and we achieved the 
assumed event rates in our protocol, suggesting our findings are unlikely to be subject to a type 1 error. We had 
crossovers during the trial, but fewer than 10% of participants (8/111), and following a post-hoc per protocol 
analysis, the treatment effect was greater in favour of abdominal cerclage. 
Women with a history of failed cerclage are rare. It is challenging to randomise such women into a trial where 
there are strong prior beliefs as to the perceived risk or benefit of the intervention and, therefore, lack of 
equipoise. This explains the length of time needed to reach the recruitment target, in spite of the national 
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multicentre trial design. We found clinicians reluctant to randomise, with many unwilling to perform, and others 
unwilling to withhold an abdominal cerclage, even in the context of a trial. In addition, women who have 
experienced multiple pregnancy losses have often extensively researched the treatment options and have a fixed 
idea of which intervention would be best for them, so are unwilling to be randomised. We were unable to collect 
accurate screening data due to the referral nature of the trial.  
The trial was underpowered to evaluate safety concerns and meaningful subgroup analysis was not possible. We 
were, therefore, unable to analyse complications pre- and post-conception with the abdominal procedure due to 
their rarity (none) and small numbers. No clinicians used laparoscopic TAC procedures and we therefore could 
not evaluate possible differences between this and other techniques. Other concerns related to abdominal 
cerclage include managing early miscarriage and infertility, were not apparent in this study. It is our experience, 
however, that evacuation of the uterus for missed miscarriage, or termination of pregnancy for fetal abnormality 
can be safely performed up to 14 weeks, leaving the abdominal cerclage in place. 
Although the trial intended to evaluate rates of neonatal death, there were none. This suggests that women with 
a prior failed pregnancy before 28 weeks tend to have fetal losses at pre-viable gestations in the second 
trimester, if they recur.  The mechanism of pregnancy failure causing late miscarriage and early preterm birth 
(resulting in neonatal death) is likely to be the same, and as we excluded early miscarriage, we therefore believe 
our fetal loss rates are a meaningful comparator across treatments, although not predefined.  
The mechanism of benefit is not clear, but our findings suggest that an abdominally placed cerclage may prevent 
the initiation of contractions. A previous study suggested that the higher the vaginal cervical cerclage is placed, 
the lower the risk of preterm birth (9) but this was in a more heterogeneous, lower risk population. In the very 
high-risk cohort of the present study, high vaginal cerclage was no better. The multiple and varied risk factors in 
the abdominal cerclage group suggests the treatment effect is unrelated to aetiology.  
 
Research Implications 
Severe complications were rare but those that did occur were in women with a vaginal procedure. Three of the 
four were related to cerclage failure, including cervical trauma at early birth, and sepsis. Multiple abdominal 
procedures associated with the abdominal cerclage may ultimately cause more longer-term morbidity and we 
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were unable to evaluate this at this time. Further research should define longer-term morbidity including after 
the menopause, along with health economic evaluation of the procedure.  
 
Conclusions 
While further research is needed to confirm the value of TAC in other high-risk groups, our findings suggest it 
is likely to be beneficial to women with previous failed vaginal cerclage. Implications for practice include the 
need to increase the availability of transabdominal cerclage for suitable women, and the training of obstetricians 
in this uncommon practice. The procedure is not technically difficult and most gynaecologists who undertake 
any form of pelvic surgery should be equipped with the fundamental skills.  
 
Contributors 
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FIGURES AND TABLES 
Figure 1: Participant flow chart with treatment allocation and exclusions 
 
 
 
Figure 2: Primary outcome by treatment allocation 
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Table 1: Variables used for minimisation by trial allocation following exclusions  
 Transabdominal 
cerclage (39) 
n (%) 
High vaginal 
cerclage (39) 
n (%) 
Low vaginal 
cerclage (33) 
n (%) 
Pregnant at 
randomisation 
20 (44⋅ 4%) 16 (35⋅ 6%) 15 (34⋅ 9%) 
Gestation at end of 
last pregnancy 
<24w 
 
31 (68⋅ 9%) 
 
26 (57⋅ 8%) 
 
29 (67⋅ 4%) 
 
 
Table 2: Maternal baseline demographic characteristics 
Treatment allocation  Transabdominal 
(N=39) 
High vaginal 
(n=39) 
Low vaginal 
(n=33) 
All 
(n=111) 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age at time of consent (years)  31⋅ 9 (5⋅ 1) 32⋅ 1 (5⋅ 3) 31⋅ 8 (5⋅ 1) 32⋅ 3 (5⋅ 4) 
BMI (kg/m2) 29⋅ 9 (6⋅ 9) 30⋅ 1 (7⋅ 0) 29⋅ 9 (6⋅ 9) 30⋅ 1 (7⋅ 0) 
Social class/occupation  n (%) n (%) n (%) n (%) 
    Managerial/professional 12 (31%) 17 (44%) 13 (39%) 42 (38%) 
    Intermediate 20 (51%) 18 (46%) 14 (42%) 52 (47%) 
    Routine/unemployed 7 (18%) 4 (10%) 6 (18%) 17 (15%) 
Ethnicity     
    White 11 (28%) 10 (26%) 12 (36%) 33 (30%) 
    Black  21 (54%) 23 (59%) 18 (55%) 62 (56%) 
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Table 3: Cohort risk factors for spontaneous preterm birth by treatment allocation 
Risk Factors  Transabdominal 
(n=39) 
High 
vaginal 
(n=39) 
Low vaginal 
(n=33) 
All 
(n=111) 
Cervical surgery 2   (5%) 6 (15%) 9 (27%) 17 (15%) 
History of late miscarriage 
(mean, SD) 
Range 
 
2⋅ 12 (1⋅ 15) 
0 - 5 
 
1⋅ 70 
(1⋅ 12) 
0 - 4 
 
1⋅ 97 
(1⋅ 08) 
0 - 5 
 
1⋅ 99 
(1⋅ 15) 
1 to 5 
History of early delivery (late 
miscarriage / PTB) 
(mean, SD) 
 
2⋅ 73 (1⋅ 12) 
 
 
2⋅ 65 
(1⋅ 03) 
 
2⋅ 91 
(1⋅ 27) 
 
2⋅ 76 
(1⋅ 13) 
 
Uterine anomaly  3   (8%) 4 (10%) 3   (9%) 10   (9%) 
Antiphospholipid syndrome 
(anticardiolipin or lupus 
anticoagulant) 
1   (3%) 2   (5%) 0   (0%) 3   (3%) 
Smoked during pregnancy 3   (8%) 1   (3%) 4 (12%) 8   (7%) 
     
Past or present history of:     
Recurrent UTIs (>2) in 
pregnancy  
3   (8%) 4 (10%) 7 (21%) 14 (13%) 
Group B Streptococcus 11 (28%) 10 (26%) 3   (9%) 24 (22%) 
    Asian  4 (10%) 5 (13%) 3 (9%) 12 (11%) 
    Other 3 (8%) 1 (3%) 0 (0%) 4 (4%) 
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Bacterial Vaginosis 3   (8%) 4 (10%) 4 (12%) 11 (10%) 
Recreational drug use  1   (3%) 0   (0%) 2   (6%) 3   (3%) 
Domestic Violence 0   (0%) 0   (0%) 0   (0%) 0   (0%) 
 
Table 4: Pregnancy outcome by randomised allocation 
Treatment  allocation  Transabdominal 
(n=39) 
High vaginal 
(n=39) 
Low vaginal 
(n=33) 
Preterm (<32 weeks)* 3 (8%) 15 (38%)  11 (33%) 
Preterm (<34 weeks)  4 (10%) 18 (46%) 13 (39%) 
Preterm (<37 weeks) 11 (28%)   21 (54%)  17 (52%) 
*primary outcome    
Live birth      38 (92%)  31 (79%) 26 (79%) 
Late Miscarriage 1 (3%) 7 (18%) 7 (21%) 
Stillbirth 0 (0%) 1 (3%) 0 (0%) 
All fetal losses 1 (3%) 8 (21%) 7 (21%) 
 
Table 5: Details of patient crossovers from randomised allocation to treatment received 
ID Randomisation Final 
procedure 
Gestation - details Outcome 
24 LVC TAC At 10+0 – patient preference 39+1 
56 LVC TAC Preconception - patient choice 36+0 
66 LVC HVC At 14+0 – patient preference 37+5 
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79 HVC TAC At 12+5 – patient preference 38+6 
87 TAC LVC At 10+6 – patient preference 38+0 
88 LVC TAC 10+2 - No vaginal cervix on 
digital examination 
37+6 
111 TAC HVC 13+3 - patient request 38+5 
133 LVC HVC 13+0 – transfer of care 38+2 
 
Table 6: Details of surgical and anaesthetic techniques 
*all other sutures were performed using monofilament suture 
 
Table 7: Primary outcomes by intention to treat and as per protocol analysis  
Procedure techniques Transabdominal 
cerclage 
(N=39) 
High vaginal cerclage 
 
(n=39) 
Low vaginal cerclage 
 
(n=33) 
 sPTB 
<32/40 
(n=3) 
Del >32/40 
(n=36) 
sPTB 
<32/40 
(n=15) 
Del >32/40 
(n=24) 
sPTB 
<32/40 
(n=11) 
Del >32/40 
(n=22) 
Regional Anaesthesia 0/3 
(0%) 
6/33  
(18%) 
14/15 
(93%) 
20/23 
(87%) 
11/11 
(100%) 
13/16 
(81%) 
Mersiline Tape* 1/3  
(33%) 
4/28  
(14%) 
12/13 
(92%) 
21/22 
(95%) 
9/10  
(90%) 
16/17 
(94%) 
>=2 sutures inserted 2/3  
(66%) 
18/28 
(64%) 
0/13  
(0%) 
1/22  
(5%) 
0/9  
(0%) 
0/17  
(0%) 
Cerclage tied anteriorly 0/3 
(0%) 
4/28  
(14%) 
13/13 
(100%) 
20/21 
(95%) 
10/10 
(100%) 
12/15 
(80%) 
Cerclage placed pre-
conception 
2/3  
(66%) 
18/36 
(50%) 
0/15 
(0%) 
0/24  
(0%) 
0/11  
(0%) 
0/22  
(0%) 
Subsequent rescue 
cerclage 
0/3  
(0%) 
0/36  
(0%) 
3/15  
(20%) 
1/24  
(4%) 
2/11  
(18%) 
0/22  
(0%) 
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 Preterm birth < 32 weeks Baby loss 
 Intention to treat 
analysis 
As per protocol 
analysis 
Intention to treat 
analysis 
As per protocol 
analysis 
TAC versus LVC 
RR 0⋅ 23 
(0⋅ 07 to 0⋅ 76) 
p=0⋅ 0078 
0⋅ 21 
(0⋅ 65 to 0⋅ 70) 
p=0⋅ 0059 
0⋅ 12 
(0⋅ 016 to 0⋅ 93) 
p=0⋅ 02 
0⋅ 11 
(0⋅ 014 to 0⋅ 86) 
p=0⋅ 018 
TAC versus HVC 
RR 0⋅ 2 
(0⋅ 063 to 0⋅ 64) 
p=0⋅ 0024 
0⋅ 19 
(0⋅ 058 to 0⋅ 59) 
p=0⋅ 001 
0⋅ 13 
(0⋅ 016 to 0⋅ 95) 
p=0⋅ 029 
0⋅ 12 
(0⋅ 015 to 0⋅ 88) 
p=0⋅ 012 
HVC versus LVC 
RR 1⋅ 15 
(0⋅ 62 to 2⋅ 16) 
p=0⋅ 81 
1⋅ 15 
(0⋅ 62 to 2⋅ 13) 
p=0⋅ 80 
0⋅ 97 
(0⋅ 39 to 2⋅ 38) 
p=1⋅ 00 
0⋅ 96 
(0⋅ 39 to 2⋅ 36) 
p=1⋅ 00 
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